Skip to main content

New story in Health from Time: WHO Suspends Study of Hydroxychloroquine as COVID-19 Treatment to Review Safety Concerns



(GENEVA) — The World Health Organization said Monday that it will temporarily drop hydroxychloroquine — the anti-malarial drug U.S. President Trump says he is taking — from its global study into experimental COVID-19 treatments, saying that its experts need to review all available evidence to date.

In a press briefing, WHO director-general Tedros Adhanom Ghebreyesus said that in light of a paper published last week in the Lancet that showed people taking hydroxychloroquine were at higher risk of death and heart problems, there would be “a temporary pause” on the hydroxychloroquine arm of its global clinical trial.

“This concern relates to the use of hydroxychloroquine and chloroquine in COVID-19,” Tedros said, adding that the drugs are approved treatments for people with malaria or autoimmune diseases. Other treatments in the trial, including the experimental drug remdesivir and an HIV combination therapy, are still being tested.

Tedros said the executive group behind WHO’s global “Solidarity” trial met on Saturday and decided to conduct a comprehensive review of all available data on hydroxychloroquine and that its use in the trial would be suspended for now.

Dr. Michael Ryan, WHO’s emergencies chief, said there was no indication of any safety problems with hydroxychloroquine in the WHO trial to date, but that statisticians would now analyze the information.

“We’re just acting on an abundance of caution based on the recent results of all the studies to to ensure that we can continue safely with that arm of the trial,” he said. WHO said it expected to have more details within the next two weeks.

Last week, Trump announced he was taking hydroxychloroquine although he has not tested positive for COVID-19. His own administration has warned the drug can have deadly side effects, and both the European Medicines Agency and the U.S. Food and Drug Administration warned health professionals last month that the drug should not be used to treat COVID-19 outside of hospital or research settings due to numerous serious side effects that in some cases can be fatal.

Hydroxychloroquine and chloroquine are approved for treating lupus and rheumatoid arthritis and for preventing and treating malaria, but no large rigorous tests have found them safe or effective for preventing or treating COVID-19.

___

Maria Cheng reported from London.

Labels:

Popular posts from this blog

New video by gymvirtual on YouTube

Rutina para adelgazar | Ejercicios para perder peso en casa ♥ ♥ LÉEME / DESPLIÉGAME ♥ ♥ Hola a todos, hoy os traigo una rutina de cardio de 25 minutos para quemar grasa y adelgazar en casa. En la web https://ift.tt/39VJREp encontraréis los calendarios de entrenamiento tanto para principiantes como para avanzados. Si quieres conseguir tú transformación en solamente 12 semanas, entra ya en http://www.pgv12.com y elige el PLAN PGV12 que más se adapte a ti. Nuestro lema: YO PUEDO CON TODO Los hashtags: #GymVirtual #YPCT #YoPuedoConTodo #PGV12 ♡♡ ¡SUSCRÍBETE! ♡♡ http://www.youtube.com/user/gymvirtual ................................................................................................................................. ♡♡ PLAN DE ENTRENAMIENTO + NUTRICIÓN 12 SEMANAS♡♡ http://www.pgv12.com ................................................................................................................................. ♡♡¡ECHA UN VISTAZO A NUESTRA TIENDA ONLINE! ♡♡ https://ift.tt/2Un...
Read more

New story in Health from Time: After Cruise Ships and Nursing Homes, Will Universities Be the Next COVID-19 Tinderboxes?

The fall semester has yet to begin, but student athletes training for the season can already be found on college campuses across the U.S. And so can COVID-19. Since the start of July there have been at least two outbreaks among student athletes, coaches, and staff—with 37 infected at the University of North Carolina (UNC) Chapel Hill and 22 at Boise State . Clusters of infection have been traced to college town bars popular with students. A common misconception is that young people with COVID-19 don’t die and therefore college re-openings pose little risk. Sadly, this isn’t the case. COVID-19 deaths in the young are rare, but they happen. Universities across the U.S. are mourning the loss of students in the lead-up to the school year, including Joshua Bush , a 30-year old nursing student at the University of South Carolina, Trevor Syphus Lee , a 27-year old senior at Utah Valley University, and Juan Garcia , a 21-year old Penn State undergraduate. One might imagine th...
Read more

New story in Health from Time: ‘We Are In Crisis.’ COVID-19 Exacerbates Problems for People With Disabilities

Jeiri Flores is normally a busy, upbeat 29-year-old. But amid the COVID-19 pandemic, her go-to thought has been dark. “If I get this,” she thinks, “I’m gonna die.” This is not an unfounded fear. Flores has cerebral palsy, uses a wheelchair and needs assistance with everyday tasks, including making food and getting dressed. Her disability means it’s tougher for her immune system to kick illnesses; she’s still recovering from a bout of pneumonia she had in January. So beating COVID-19 could easily mean a protracted battle and months in a hospital—a prospect that comes with a cascading series of challenges unique to people with disabilities. At a time when all Americans are facing unforeseen obstacles and concerned about their futures, Flores and more than 60 million Americans with disabilities like her are facing perhaps the toughest road of all. With hospitals restricting visitors amid the pandemic, Flores and others who rely on family and aides for assistance and advoca...
Read more